Intensive Blood Pressure Intervention in Stroke (IBIS) Trial — IBIS  

Ischemic Stroke Clinical Trial

Official title: Intensive Blood Pressure Intervention in Stroke (IBIS) Trial

Status Withdrawn

Clinical Trial Summary

The investigators propose to conduct a multicenter randomized controlled trial to test the effect of a systolic blood pressure target of less than 120 mmHg (intensive treatment) compared to a target of less than 140 mmHg (standard treatment) on the risk of total recurrent stroke (ischemic and hemorrhagic) among patients with a recent ischemic stroke. The study findings will help in the development of clinical guidelines for blood pressure management among patients with ischemic stroke and will have an important global impact on reducing stroke-related morbidity and mortality.

Clinical Trial Description

Stroke is a leading cause of death and long-term disability worldwide, especially in the elderly population. Hypertension is a major risk factor for stroke. Previous clinical trials have documented that blood pressure (BP) reduction lowers the risk of incident and recurrent stroke. The Secondary Prevention of Small Subcortical Strokes (SPS3) trial reported that a systolic BP target of <130 mmHg was associated with a non-significant (p=0.08) 19% reduction in recurrent stroke compared to a systolic BP target of 130-149 mmHg among 3,020 patients with recent lacunar stroke. The Systolic Blood Pressure Intervention Trial (SPRINT) showed that a systolic BP target of <120 mmHg was associated with a 25% reduction in cardiovascular disease (CVD) and 27% reduction in all-cause mortality compared to a systolic BP target of <140 mmHg. In the SPRINT trial, patients with a history of stroke were excluded. Therefore, the optimal BP targets for the secondary prevention of stroke remain uncertain. The investigators propose to conduct a multicenter randomized controlled trial to test the following hypotheses: Primary Hypothesis: In patients with a recent ischemic stroke and a systolic BP ≥140 mmHg (or systolic BP ≥135 mmHg if on ≥1 antihypertensive medication), an intensive treatment strategy (a systolic BP target of <120 mmHg) will reduce the risk of total recurrent stroke (ischemic and hemorrhagic) events compared to a standard treatment strategy (a systolic BP target of <140 mmHg) over a follow-up period of up to four years. The targeted mean systolic BP difference between the two randomized groups will be ≥15 mmHg. Subgroup Hypotheses: The effect of the intensive treatment strategy compared to the standard treatment strategy for the primary study outcome (total recurrent stroke) will be consistent in the following subgroups: - Men and women - Age <65 and ≥65 years at baseline - Systolic BP levels at baseline (tertiles) - Subtypes of ischemic stroke - Diabetes and non-diabetes - American College of Cardiology/America Heart Association atherosclerotic CVD risk scores (tertiles) Secondary Hypotheses: The intensive treatment strategy will reduce the risk of the following secondary outcomes compared to the standard treatment strategy: - Major CVD events - a composite outcome including myocardial infarction (MI), non-MI acute coronary syndrome, stroke, hospitalized or treated heart failure, and CVD deaths; - Individual CVD events, i.e., myocardial infarction; acute coronary syndrome; hospitalized or treated heart failure; or CVD mortality; - All-cause mortality; - Cognitive decline and all-cause dementia; and - Health-related quality of life. Adverse Events: The intensive treatment strategy does not increase the risk of adverse events, such as hypotension, syncope, bradycardia, electrolyte abnormalities, acute kidney injury, incident chronic kidney disease (CKD, defined as eGFR <60 ml/min/1.73m2 and ≥30% decrease from baseline eGFR), injurious falls, or hospitalization compared to the standard treatment strategy. The proposed trial will recruit 13,396 patients with a history of ischemic stroke from approximately 140 hospitals within the US-China Collaborative Stroke Clinical Trial Network. Eligible patients will be aged ≥40 years; have a mean systolic BP ≥140 mmHg or systolic BP ≥135 mmHg on one or more antihypertensive medications; and have had a recent (more than 3 months and less than 1 year since last acute onset) symptomatic ischemic stroke confirmed by computed tomography (CT) or magnetic resonance imaging (MRI). Principal exclusion criteria will include intracranial and extracranial stenosis (symptomatic stenosis ≥50% or asymptomatic stenosis ≥70%); severe heart failure (NY Heart Association class III and IV); disabling stroke (modified Rankin score of ≥4); or previous intracranial hemorrhage from non-traumatic causes. The proposed trial has 90% statistical power to detect a 20% reduction (hazard ratio of 0.80) in total stroke (ischemic and hemorrhagic) between the intensive and standard treatment groups at a 2-sided significance level of 0.05. We further assume an event rate of recurrent stroke of 2.5% per year in the control group, a two-year uniform recruitment period, total study length of four years, and a 2% per year loss to follow-up rate. Based on data from prospective cohort studies and two-year follow-up of the China Antihypertensive Trial in Acute Ischemic Stroke (CATIS), the annual event rate of recurrent total stroke was greater than 3% after the first 3 months following stroke onset in Chinese patients. Impact: Optimal BP levels for the secondary prevention of ischemic stroke have not been well defined. The results from the proposed trial will provide evidence as to whether intensive BP treatment to achieve a systolic BP target of <120 mmHg has additional benefits over standard treatment of systolic BP <140 mmHg on recurrent stroke. These findings will help in the development of clinical guidelines for BP management among patients with ischemic stroke and will have an important clinical impact globally. ;

Related Conditions & MeSH terms

• Ischemic Stroke
• Stroke

• NCT number: NCT03585595
• Study type: Interventional
• Source: Tulane University
• Status: Withdrawn
• Phase: Phase 3
• Start date: January 1, 2018
• Completion date: December 31, 2022